...Janssen Pharmaceutical Research and Development on the study, which evaluated eight products including approved drugs bosentan... ...chip platform to enable better decision making in drug discovery and development." Geraldine Hamilton, Emulate Bosentan...
...metabolic disorders such as phenylketonuria, Pompe disease and Gaucher disease. Drugs for PAH include Tracleerbosentan... ...and Ofev/Vargatef nintedanib from Boehringer Ingelheim GmbH (Ingelheim, Germany). Also included are the APIs for bosentan...
...FDA approved a 32 mg tablet of Tracleerbosentan to treat pulmonary arterial hypertension in children... ...Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said Tracleer... ...Jan. 27 ). Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tracleerbosentan Business: Cardiovascular
Mary Romeo
Tracleer
Idorsia...
...FDA approved a 32 mg tablet of Tracleerbosentan to treat pulmonary arterial hypertension in children... ...Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said Tracleer... ...discovery operations and early stage assets (see BioCentury Extra, Jan. 26 and June 16) .
Mary Romeo
Tracleer
Idorsia...
...pointed to the spheroids’ ability to pick out cytotoxicity of the endothelin receptor antagonists Tracleerbosentan... ...prolonged expression of BSEPs is a potential advantage of the system. Johnson & Johnson obtained Tracleer...
...bosentan for congestive heart failure (CHF). Roche had discontinued a Phase III trial of bosentan... ...known Orphan indication, pulmonary arterial hypertension (PAH), in parallel with heart failure. FDA approved Tracleerbosentan... ...tied to Tracleer. Despite trials in numerous other indications, the biotech never succeeded in expanding Tracleer’s...